These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 32075132)
21. Mutant p53 rescue and modulation of p53 redox state. Bykov VJ; Lambert JM; Hainaut P; Wiman KG Cell Cycle; 2009 Aug; 8(16):2509-17. PubMed ID: 19633417 [TBL] [Abstract][Full Text] [Related]
22. Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy. Olotu FA; Soliman MES J Cell Biochem; 2019 Jan; 120(1):951-966. PubMed ID: 30160791 [TBL] [Abstract][Full Text] [Related]
23. Awakening the "guardian of genome": reactivation of mutant p53. Binayke A; Mishra S; Suman P; Das S; Chander H Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219 [TBL] [Abstract][Full Text] [Related]
24. Evaluating Drosophila p53 as a model system for studying cancer mutations. Herzog G; Joerger AC; Shmueli MD; Fersht AR; Gazit E; Segal D J Biol Chem; 2012 Dec; 287(53):44330-7. PubMed ID: 23135266 [TBL] [Abstract][Full Text] [Related]
25. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. Léveillard T; Andera L; Bissonnette N; Schaeffer L; Bracco L; Egly JM; Wasylyk B EMBO J; 1996 Apr; 15(7):1615-24. PubMed ID: 8612585 [TBL] [Abstract][Full Text] [Related]
26. Mechanisms of mutant p53 stabilization in cancer. Frum RA; Grossman SR Subcell Biochem; 2014; 85():187-97. PubMed ID: 25201195 [TBL] [Abstract][Full Text] [Related]
27. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Muscolini M; Montagni E; Caristi S; Nomura T; Kamada R; Di Agostino S; Corazzari M; Piacentini M; Blandino G; Costanzo A; Sakaguchi K; Tuosto L Cell Cycle; 2009 Oct; 8(20):3396-405. PubMed ID: 19806023 [TBL] [Abstract][Full Text] [Related]
28. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V Oncotarget; 2016 Mar; 7(11):11817-37. PubMed ID: 26943582 [TBL] [Abstract][Full Text] [Related]
29. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological reactivation of p53 as a strategy to treat cancer. Zawacka-Pankau J; Selivanova G J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071 [TBL] [Abstract][Full Text] [Related]
31. Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53's tumor suppression. Węsierska-Gądek J Future Med Chem; 2018 Apr; 10(7):755-777. PubMed ID: 29569948 [TBL] [Abstract][Full Text] [Related]
32. Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53. Yu X; Blanden A; Tsang AT; Zaman S; Liu Y; Gilleran J; Bencivenga AF; Kimball SD; Loh SN; Carpizo DR Mol Pharmacol; 2017 Jun; 91(6):567-575. PubMed ID: 28320780 [TBL] [Abstract][Full Text] [Related]
33. Discovery of compounds that reactivate p53 mutants in vitro and in vivo. Durairaj G; Demir Ö; Lim B; Baronio R; Tifrea D; Hall LV; DeForest JC; Lauinger L; Jebril Fallatah MM; Yu C; Bae H; Lin DW; Kim JK; Salehi F; Jang C; Qiao F; Lathrop RH; Huang L; Edwards R; Rychnovsky S; Amaro RE; Kaiser P Cell Chem Biol; 2022 Sep; 29(9):1381-1395.e13. PubMed ID: 35948006 [TBL] [Abstract][Full Text] [Related]
34. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights. Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312 [TBL] [Abstract][Full Text] [Related]
35. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. Liu WL; Midgley C; Stephen C; Saville M; Lane DP J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899 [TBL] [Abstract][Full Text] [Related]
36. Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C. Miller JJ; Kwan K; Blanchet A; Orvain C; Mellitzer G; Smith J; Lento C; Nouchikian L; Omoregbee-Leichnitz S; Sabatou M; Wilson D; Gaiddon C; Storr T J Inorg Biochem; 2023 May; 242():112164. PubMed ID: 36871418 [TBL] [Abstract][Full Text] [Related]
37. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668 [TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNAs: p53's secret weapon in the fight against cancer? Dangelmaier E; Lazar SB; Lal A PLoS Biol; 2019 Feb; 17(2):e3000143. PubMed ID: 30759134 [TBL] [Abstract][Full Text] [Related]
39. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393 [TBL] [Abstract][Full Text] [Related]
40. Structural studies on mechanisms to activate mutant p53. Viadiu H; Fronza G; Inga A Subcell Biochem; 2014; 85():119-32. PubMed ID: 25201192 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]